Alexander Charney, MD, PhD Email Alexander Charney
-
- Positions
- ASSISTANT PROFESSOR | Genetics and Genomic Sciences
- ASSISTANT PROFESSOR | Psychiatry
- ASSISTANT PROFESSOR | Neuroscience
- ASSISTANT PROFESSOR | Neurosurgery
-
- Language
- English
-
- Hospital Affiliations
- New York Eye and Ear Infirmary of Mount Sinai
- Mount Sinai Queens
- Mount Sinai Beth Israel
- The Mount Sinai Hospital
- Mount Sinai Brooklyn
- Mount Sinai Morningside and Mount Sinai West
Alex Charney is an Assistant Professor with primary appointments in the Departments of Psychiatry and Genetics & Genomic Sciences, as well as secondary appointments in the Departments of Neuroscience and Neurosurgery. He is also Co-Director of the Mount Sinai Clinical Intelligence Center.
As a physician-scientist specializing in the neurobiology of neuropsychiatric illness, his work is focused on translating genomic discoveries to experimental therapeutics. He received his MD and PhD under the mentorship of Pamela Sklar, MD, PhD, and Eric Schadt, PhD, two of the world's foremost experts on large-scale genomics and multiscale biology. Within his field, Alex is best known for using multiple types of genomic data to dissect the clinical features of schizophrenia and bipolar disorder, developing a novel framework for human brain research with the Living Brain Project, and advocating for the rapid translation of genomic findings to early-phase clinical trials of experimental therapeutics. His expertise is in the genetic architecture of neuropsychiatric disease and integrative approaches to analyzing multiscale datasets. He has been the lead data scientist on genetic studies of schizophrenia and bipolar disorder, including genome-wide association studies, copy number variant studies and rare sequencing variant studies. Currently, he plays a lead role in several of the largest studies in the field of psychiatric genomics. Alex has established a unique approach to human brain research as the founder and primary investigator of the Living Brain Project, a multiscale, data-driven investigation of the human brain wherein a single living population is being studied using all of the tools available for human-subject neuroscience, including the tools of molecular and cellular neurobiology that to date have been applied primarily in the post-mortem setting. In the setting of the COVID-19 pandemic, Alex utilized his training as a clinician and scientist to lead the research response at the epicenter of New York City.
Research Topic
Bioinformatics, Computational Neuroscience, Genetics, Genetics of Movement disorders, Genomics, Human Genetics and Genetic Disorders, Neuro-degeneration/protection, Neurobiology, Neuroscience, Parkinson's Disease, Personalized Medicine, Pharmacogenomics, Psychiatry, Schizophrenia
Multi-Disciplinary Training Area
Neuroscience [NEU]
Education
BA, New York University
MD, Icahn School of Medicine at Mount Sinai
Postdoc, Icahn School of Medicine at Mount Sinai
PhD, Icahn School of Medicine at Mount Sinai
Resident, Icahn School of Medicine at Mount Sinai
Language
English
2020
Friedman Brain Institute Scholar
Friedman Brain Institute, Icahn School of Medicine at Mount Sinai
2018
Chief Resident for Research
Icahn School of Medicine at Mount Sinai
2018
Travel Award
Pathways to Drugs Meeting
2018
Young Investigator Award
NARSAD
2017
Fellow
Leon Levy Foundation
2016
Outstanding Resident Award Program Awardee
National Institute of Mental Health
2016
Friedman Brain Institute Scholars Awardee
Friedman Brain Institute, Icahn School of Medicine at Mount Sinai
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Charney did not report having any of the following types of financial relationships with industry during 2021 and/or 2022: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website.
Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.